The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.

By A. Xu, Yu Wang, H. Keshaw, L. Xu, K. Lam, G. Cooper. Journal of Clinical Investigation, 2003

1,319 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/3a2ab85d7f48d6b2e9768626ea890746fcc30c76

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Herbert Tilg
2. A. Moschen
3. K. Walsh
4. P. Scherer
5. N. Ouchi
6. Haiming Cao
7. M. Blüher

In Epidemiology

1. Herbert Tilg
2. P. Scherer
3. A. Moschen
4. K. Walsh
5. S. Klein
6. M. Pinzani
7. A. Okunade
8. B. Patterson

In Physiology

1. Sushil Kumar Jain
2. P. Scherer
3. Herbert Tilg
4. Toshimasa Yamauchi
5. A. Moschen
6. Takashi Kadowaki
7. N. Ouchi
8. K. Walsh

Citations in the corpus

• Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis Through Adipose Tissue Crosstalk (2016, background): “Adiponectin has repeatedly been shown to enhance insulin sensitivity (Berg et al., 2001) and maintains healthy adipose tissue expansion while rescuing ectopic lipid accumulation in animal models (Xu et al., 2003; Yamauchi et al., 2001).”
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). (2016, background): “Enhanced liver fibrosis has been demonstrated in mice lacking adiponectin [84], while delivery of recombinant adiponectin significantly improved steatohepatitis in mice [86].”
• Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies (2015, background): “Various studies have suggested a link between lower circulating levels of adiponectin and increased liver fat content and the degree of hepatic insulin resistance.(327) Administration of adiponectin decreased hepatic insulin resistance in a mouse model of obesity and diabetes through the activation ”
• Adipokines in inflammation and metabolic disease (2011, background): “Similarly, the acute administration of adiponectin to ob/ob mice improves fatty liver disease through suppression of TNF productio”
• Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. (2013, methodology): “enhances fatty acid oxidation, and increases insulin sensitivity (Berg et al., 2001; Xu et al., 2003).”
• Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, background): “These therapeutic effects resulted partly from the ability of adiponectin to increase carnitine palmitoyltransferase I activity and enhance hepatic fatty acid oxidation, while decreased the activities of two key enzymes involved in fatty acid synthesis, including acetyl-CoA carboxylase and fatty aci”
• Energy Metabolism in the Liver (2014, neutral): “Adiponectin stimulates βoxidation in the liver and improves liver insulin sensitivity (288, 291).”